397 related articles for article (PubMed ID: 28888969)
1. mTOR-related neuropathology in mutant tsc2 zebrafish: Phenotypic, transcriptomic and pharmacological analysis.
Scheldeman C; Mills JD; Siekierska A; Serra I; Copmans D; Iyer AM; Whalley BJ; Maes J; Jansen AC; Lagae L; Aronica E; de Witte PAM
Neurobiol Dis; 2017 Dec; 108():225-237. PubMed ID: 28888969
[TBL] [Abstract][Full Text] [Related]
2. TrkB hyperactivity contributes to brain dysconnectivity, epileptogenesis, and anxiety in zebrafish model of Tuberous Sclerosis Complex.
Kedra M; Banasiak K; Kisielewska K; Wolinska-Niziol L; Jaworski J; Zmorzynska J
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2170-2179. PubMed ID: 31932427
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex.
Serra I; Scheldeman C; Bazelot M; Whalley BJ; Dallas ML; de Witte PAM; Williams CM
Behav Brain Res; 2019 May; 363():135-144. PubMed ID: 30684511
[TBL] [Abstract][Full Text] [Related]
4. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
5. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
eNeuro; 2015; 2(6):. PubMed ID: 26693177
[TBL] [Abstract][Full Text] [Related]
6. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
7. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
8. Hyperactivation of mTORC1 in a double hit mutant zebrafish model of tuberous sclerosis complex causes increased seizure susceptibility and neurodevelopmental abnormalities.
De Meulemeester AS; Heylen L; Siekierska A; Mills JD; Romagnolo A; Van Der Wel NN; Aronica E; de Witte PAM
Front Cell Dev Biol; 2022; 10():952832. PubMed ID: 36238691
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
10. Zebrafish model of tuberous sclerosis complex reveals cell-autonomous and non-cell-autonomous functions of mutant tuberin.
Kim SH; Speirs CK; Solnica-Krezel L; Ess KC
Dis Model Mech; 2011 Mar; 4(2):255-67. PubMed ID: 20959633
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
[TBL] [Abstract][Full Text] [Related]
12. Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models.
Magri L; Cominelli M; Cambiaghi M; Cursi M; Leocani L; Minicucci F; Poliani PL; Galli R
Dis Model Mech; 2013 Sep; 6(5):1185-97. PubMed ID: 23744272
[TBL] [Abstract][Full Text] [Related]
13. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
14. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress.
Zimmer TS; Korotkov A; Zwakenberg S; Jansen FE; Zwartkruis FJT; Rensing NR; Wong M; Mühlebner A; van Vliet EA; Aronica E; Mills JD
Brain Pathol; 2021 Sep; 31(5):e12949. PubMed ID: 33786950
[TBL] [Abstract][Full Text] [Related]
16. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
17. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
18. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex.
Nie D; Chen Z; Ebrahimi-Fakhari D; Di Nardo A; Julich K; Robson VK; Cheng YC; Woolf CJ; Heiman M; Sahin M
J Neurosci; 2015 Jul; 35(30):10762-72. PubMed ID: 26224859
[TBL] [Abstract][Full Text] [Related]
19. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
Tee AR; Sampson JR; Pal DK; Bateman JM
Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
[TBL] [Abstract][Full Text] [Related]
20. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
